First, we used eight known enhancer hijacking target genes including MYC (9), BCL2 (8), CCNE1 (37), TERT (7), IGF2 (13,37) (in two tumor types), IGF2BP3 (38) and IRS4 (13) to test the sensitivities. The gene discussed is BCL2; the disease is neoplasm.